Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 3,975 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 3,975 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $19.98, for a total value of $79,420.50. Following the sale, the chief financial officer directly owned 318,789 shares of the company’s stock, valued at $6,369,404.22. This represents a 1.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.

Hims & Hers Health Trading Down 3.9%

HIMS opened at $19.54 on Wednesday. The stock’s fifty day moving average is $20.26 and its two-hundred day moving average is $34.02. The company has a market capitalization of $4.45 billion, a P/E ratio of 38.31, a PEG ratio of 2.31 and a beta of 2.32. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same period last year, the business posted $0.11 EPS. Hims & Hers Health’s quarterly revenue was up 28.4% on a year-over-year basis. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded GLP‑1 partnership and new weight‑loss membership: Hims renewed and broadened its collaboration with Novo Nordisk to offer a wider set of FDA‑approved GLP‑1 medicines (including Wegovy options) and launched a tiered weight‑loss membership (intro $39, then $149/month; meds priced separately). This expands prescription revenue potential and recurring revenue mix. Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership – Has The Bull Case Changed?
• Positive Sentiment: Platform expansion (Labs, hormone therapy, weight programs): Management is broadening the digital‑first care offering to increase average revenue per customer and lifetime value as it scales internationally. This supports longer‑term growth and customer engagement. Hims & Hers Advances a Consumer-Centric Digital Health Platform
• Neutral Sentiment: Analyst/sector commentary: Contrarian coverage highlights HIMS as a consumer momentum play despite regulatory noise — a sentiment piece that can attract value‑oriented buyers but is not a catalyst by itself. 3 Sectors to Buy While They’re Down and 1 to Walk Away From
• Neutral Sentiment: Insider sale disclosed: CFO Oluyemi Okupe sold ~3,975 shares under a pre‑arranged Rule 10b5‑1 plan. The sale reduced his stake slightly but was planned in advance, which lessens the negative signal. Insider Sale Filing
• Neutral Sentiment: Price action note: Coverage flagged a recent intraday dip in the stock — reflects short‑term volatility and mixed newsflow rather than a single clear fundamental shift. Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Tariff risk to drug partnership: Reporting warns of a new tariff that could threaten a key drug partnership and margin profile if it affects medication sourcing or pricing — this is a material regulatory/ policy risk to the prescription side of the business. Hims & Hers Faces Dual Challenges: New Tariff Threatens Key Drug Partnership
• Negative Sentiment: Customer‑service platform breach: Hims reported a social‑engineering incident on a third‑party customer service platform with limited customer data exposure; medical records were not affected. Still, any breach raises reputational and compliance risk and could increase costs (security, notifications, potential regulatory scrutiny). Hims & Hers says limited data stolen in social engineering attack

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on HIMS shares. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Evercore set a $24.00 target price on Hims & Hers Health in a research note on Tuesday, February 24th. Leerink Partners boosted their target price on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research note on Monday, March 16th. Finally, Citigroup upgraded Hims & Hers Health from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $13.25 to $24.00 in a research note on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $31.71.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Steward Partners Investment Advisory LLC grew its position in shares of Hims & Hers Health by 47.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 2,698 shares of the company’s stock valued at $134,000 after purchasing an additional 863 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Hims & Hers Health by 75.6% in the second quarter. Russell Investments Group Ltd. now owns 46,446 shares of the company’s stock valued at $2,315,000 after purchasing an additional 20,003 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in shares of Hims & Hers Health by 2.0% in the second quarter. New York State Common Retirement Fund now owns 59,945 shares of the company’s stock valued at $2,988,000 after purchasing an additional 1,200 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.